Mihael Hristos Polymeropoulos Acquires 10,000 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of Vanda Pharmaceuticals stock in a transaction on Tuesday, February 25th. The stock was acquired at an average price of $4.46 per share, with a total value of $44,600.00. Following the completion of the purchase, the chief executive officer now directly owns 2,331,730 shares of the company’s stock, valued at approximately $10,399,515.80. The trade was a 0.43 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Vanda Pharmaceuticals Stock Up 5.6 %

Shares of Vanda Pharmaceuticals stock opened at $4.71 on Thursday. Vanda Pharmaceuticals Inc. has a 12-month low of $3.71 and a 12-month high of $6.75. The stock has a 50 day moving average price of $4.59 and a two-hundred day moving average price of $4.80. The stock has a market capitalization of $274.67 million, a P/E ratio of -14.72 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $53.19 million during the quarter, compared to analysts’ expectations of $51.00 million. Sell-side analysts anticipate that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

VNDA has been the topic of a number of recent research reports. HC Wainwright raised their price target on shares of Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They set a “hold” rating on the stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently bought and sold shares of VNDA. Mackenzie Financial Corp bought a new position in shares of Vanda Pharmaceuticals in the fourth quarter worth about $240,000. Squarepoint Ops LLC grew its holdings in Vanda Pharmaceuticals by 186.4% in the 4th quarter. Squarepoint Ops LLC now owns 71,131 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 46,293 shares during the last quarter. Two Sigma Advisers LP lifted its holdings in shares of Vanda Pharmaceuticals by 11.2% during the fourth quarter. Two Sigma Advisers LP now owns 156,300 shares of the biopharmaceutical company’s stock worth $749,000 after buying an additional 15,700 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Vanda Pharmaceuticals by 94.7% during the fourth quarter. Two Sigma Investments LP now owns 199,460 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 97,017 shares during the last quarter. Finally, Stonepine Capital Management LLC bought a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at approximately $120,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.